Skip to content
BMRN·Nasdaq·US

BioMarin

BioMarin is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Based in San Rafael, California and founded in 1997, it has eight commercial therapies and a clinical and preclinical pipeline. Its customers include specialty pharmacies, hospitals, non-U.S. government agencies, distributors and wholesalers.

Source: SEC 10-K Feb 26, 2026

Recent Activity

Updated Sep 24, 2026
–BioMarin is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities.
–BioMarin's VOXZOGO is nearing a $1 billion sales milestone.
–For POMBILITI + OPFOLDA, the company said the commercial opportunity depends on patients switching from other Pompe disease therapies as evidence and real-world data develop.

Past updates are part of the Pro plan.

Thematic Position

BMRN

Relationship Groups

Customers2
Partners1
Licensing3
Competitors12

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tariffnational security review
U.S. tariffs on pharmaceuticals and Commerce Department national security investigation raise BioMarin import costs
SEC 10-KFeb 26, 2026

The full regulatory passage is part of the Pro plan.

9 more · Regulatory and geopolitical insights are part of the Pro plan.